# Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS

> **NCT02923986** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Bio-Path Holdings, Inc.**

## Conditions studied

- Chronic Myelogenous Leukemia, Ph1-Positive
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** BP1001 (varying dose)
- **DRUG:** BP1001 (fixed dose)
- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT02923986
- **Lead sponsor:** Bio-Path Holdings, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-09-01
- **Primary completion:** 2020-05-27
- **Final completion:** 2020-05-27
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No enrollment
- **Last updated:** 2020-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02923986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02923986, "Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02923986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*